Logo image of EPRX.CA

EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock Fundamental Analysis

Canada - TSX:EPRX - CA29842P1053 - Common Stock

8.88 CAD
+0.09 (+1.02%)
Last: 11/20/2025, 7:00:00 PM
Fundamental Rating

3

EPRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 21 industry peers in the Biotechnology industry. While EPRX has a great health rating, there are worries on its profitability. EPRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EPRX had negative earnings in the past year.
In the past year EPRX has reported a negative cash flow from operations.
EPRX had negative earnings in each of the past 5 years.
In the past 5 years EPRX always reported negative operating cash flow.
EPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFEPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a decent Return On Assets value of -31.81%, EPRX is doing good in the industry, outperforming 66.67% of the companies in the same industry.
EPRX's Return On Equity of -32.63% is fine compared to the rest of the industry. EPRX outperforms 76.19% of its industry peers.
Industry RankSector Rank
ROA -31.81%
ROE -32.63%
ROIC N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPRX.CA Yearly ROA, ROE, ROICEPRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EPRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX.CA Yearly Profit, Operating, Gross MarginsEPRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, EPRX has more shares outstanding
Compared to 5 years ago, EPRX has more shares outstanding
There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EPRX.CA Yearly Shares OutstandingEPRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EPRX.CA Yearly Total Debt VS Total AssetsEPRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

An Altman-Z score of 79.89 indicates that EPRX is not in any danger for bankruptcy at the moment.
EPRX has a better Altman-Z score (79.89) than 100.00% of its industry peers.
EPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 79.89
ROIC/WACCN/A
WACCN/A
EPRX.CA Yearly LT Debt VS Equity VS FCFEPRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 23.98 indicates that EPRX has no problem at all paying its short term obligations.
The Current ratio of EPRX (23.98) is better than 95.24% of its industry peers.
A Quick Ratio of 23.98 indicates that EPRX has no problem at all paying its short term obligations.
EPRX has a Quick ratio of 23.98. This is amongst the best in the industry. EPRX outperforms 95.24% of its industry peers.
Industry RankSector Rank
Current Ratio 23.98
Quick Ratio 23.98
EPRX.CA Yearly Current Assets VS Current LiabilitesEPRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

EPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.74%, which is quite good.
EPS 1Y (TTM)15.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.13% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.42%
EPS Next 2Y8.6%
EPS Next 3Y17%
EPS Next 5Y13.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX.CA Yearly Revenue VS EstimatesEPRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M
EPRX.CA Yearly EPS VS EstimatesEPRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EPRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EPRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX.CA Price Earnings VS Forward Price EarningsEPRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX.CA Per share dataEPRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

EPRX's earnings are expected to grow with 17.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.6%
EPS Next 3Y17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EPRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUPRAXIA PHARMACEUTICALS INC

TSX:EPRX (11/20/2025, 7:00:00 PM)

8.88

+0.09 (+1.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05
Earnings (Next)N/A N/A
Inst Owners5.35%
Inst Owner ChangeN/A
Ins Owners19.13%
Ins Owner ChangeN/A
Market Cap449.33M
Revenue(TTM)N/A
Net Income(TTM)-29.37M
Analysts84
Price Target11.22 (26.35%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)25.33%
EPS NY rev (3m)15.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.56
P/tB 3.56
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS2.49
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.81%
ROE -32.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 214.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.98
Quick Ratio 23.98
Altman-Z 79.89
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.53%
Cap/Depr(5y)142.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.3%
EPS Next Y20.42%
EPS Next 2Y8.6%
EPS Next 3Y17%
EPS Next 5Y13.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.14%
EBIT Next 3YN/A
EBIT Next 5Y16.98%
FCF growth 1Y-0.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.17%
OCF growth 3YN/A
OCF growth 5YN/A

EUPRAXIA PHARMACEUTICALS INC / EPRX.CA FAQ

What is the fundamental rating for EPRX stock?

ChartMill assigns a fundamental rating of 3 / 10 to EPRX.CA.


Can you provide the valuation status for EUPRAXIA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to EUPRAXIA PHARMACEUTICALS INC (EPRX.CA). This can be considered as Overvalued.


Can you provide the profitability details for EUPRAXIA PHARMACEUTICALS INC?

EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) has a profitability rating of 1 / 10.


How financially healthy is EUPRAXIA PHARMACEUTICALS INC?

The financial health rating of EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) is 8 / 10.